A. Nomeir

发表

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

E. Lees, T. Fischmann, P. Kirschmeier, 2010, Molecular Cancer Therapeutics.

linical Development aciclib ( SCH 727965 ) , a Novel and Potent Ther lin-Dependent Kinase Inhibitor

Parry, E. Lees, P. Kirschmeier, 2010 .

Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein

S. Peltz, X. Tong, Z. Gu, 2013, Antimicrobial Agents and Chemotherapy.

Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

M. Snow, P. Weber, P. Kirschmeier, 2002, Journal of medicinal chemistry.

ADME Strategies in Lead Optimization

A. Nomeir, 2010 .

High-performance liquid chromatographic analysis of the anti-tumor agent SCH 66336 in cynomolgus monkey plasma and evaluation of its chiral inversion in animals.

A. Nomeir, C. Lin, H. Kim, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

Walter A. Korfmacher, W. R. Bishop, Jianping Chen, 1999, Cancer Chemotherapy and Pharmacology.

Studies to Investigate the in Vivo Therapeutic Window of the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide (LY411,575) in the CRND8 Mouse

Lynn A. Hyde, G. Higgins, J. Clader, 2006, Journal of Pharmacology and Experimental Therapeutics.

Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity

Qian Huang, D. Graham, C. Coburn, 2013, ChemMedChem.

Mechanism-Based Inactivation of Human Cytochrome P 450 3 A 4 by Two Piperazine-Containing Compounds s

A. Nomeir, L. Furge, Amanda K. Bolles, 2014 .

Mechanism-Based Inactivation of Human Cytochrome P450 3A4 by Two Piperazine-Containing Compounds

A. Nomeir, L. Furge, Amanda K. Bolles, 2014, Drug Metabolism and Disposition.

Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates.

A. Nomeir, L. Favreau, C. Ruegg, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes.

A. Nomeir, L. Favreau, C. Lin, 1999, Drug Metabolism And Disposition.

Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice

A. Nomeir, S. Narula, A. Golovko, 2005, European journal of immunology.

Comparative disposition of 2,3-epoxy-1-propanol (glycidol) in rats following oral and intravenous administration.

A. Nomeir, B. Ghanayem, N. F. Ferrala, 1995, Journal of toxicology and environmental health.

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

E. Lees, T. Fischmann, P. Kirschmeier, 2010, ACS medicinal chemistry letters.

Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.

Lynn A. Hyde, W. Greenlee, Mark D. McBriar, 2008, Bioorganic & medicinal chemistry letters.

Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.

Z. Gu, A. Nomeir, F. Lahser, 2016, Bioorganic & medicinal chemistry letters.

Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.

Z. Gu, C. Espiritu, H. Ren, 2013, Bioorganic & Medicinal Chemistry Letters.

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.

E. Asante-Appiah, M. Dwyer, A. Nomeir, 2018, Bioorganic & medicinal chemistry letters.

High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma.

A. Nomeir, P. Statkevich, C. Lin, 2001, Journal of pharmaceutical and biomedical analysis.

High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.

A. Nomeir, P. Statkevich, C. Lin, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Comparative toxicity, cholinergic effects, and tissue levels of S,S,S,-tri-n-butyl phosphorotrithioate (DEF) to channel catfish (ictalurus punctatus) and blue crabs (callinectes sapidus)

A. Nomeir, M. Abou‐Donia, C. Habig, 1986 .

Generic fast gradient liquid chromatography/tandem mass spectrometry techniques for the assessment of the in vitro permeability across the blood-brain barrier in drug discovery.

Fei Liu, A. Nomeir, I. Chu, 2002, Rapid communications in mass spectrometry : RCM.

Metabolism and disposition of the flame retardant tris(2,3-dibromopropyl)phosphate in the rat.

H. Matthews, A. Nomeir, 1983, Toxicology and applied pharmacology.

DMD060459 2087..2096

A. Nomeir, L. Furge, Amanda K. Bolles, 2014 .

Identification of a novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]-2-oxo-(1,4'-bipiperidine) as a dual NK(1)/NK(2) antagonist.

K. Ng, C. Rizzo, J. Hey, 2002, Bioorganic & medicinal chemistry letters.

Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes.

A. Nomeir, L. Favreau, C. Lin, 2000, Rapid communications in mass spectrometry : RCM.

Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies

A. Nomeir, L. Favreau, J. Palamanda, 1998 .

Isolation of circulating metabolites in drug discovery using high-performance liquid chromatography, and their identification by liquid chromatography coupled with tandem mass spectrometry and nuclear magnetic resonance spectroscopy

K. Cox, A. Nomeir, M. Bryant, 2002 .

Analysis of isepamicin in human plasma by radioimmunoassay, microbiologic assay, and high-performance liquid chromatography.

A. Nomeir, C. Lin, J. Veals, 1997, Therapeutic drug monitoring.

Cyclic urea derivatives as potent NK1 selective antagonists.

J. Lachowicz, A. Nomeir, C. Morgan, 2005, Bioorganic & medicinal chemistry letters.

Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].

D. Loebenberg, F. Menzel, A. Nomeir, 2006, Bioorganic & medicinal chemistry letters.

Single‐Dose Pharmacokinetics of Isepamicin in Young and Geriatric Volunteers

A. Nomeir, M. Cayen, E. Radwanski, 1997, Journal of clinical pharmacology.

Pharmacological Characterization of a Novel α2C-Adrenoceptor Agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N′-methylurea (Compound A)

Walter A. Korfmacher, Y. Wan, S. Umland, 2011, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological Characterization of a Novel (cid:1) 2C -Adrenoceptor Agonist N- [3,4-dihydro-4-(1 H -imidazol-4-ylmethyl)-2 H -1, 4-benzoxazin-6-yl]- N -ethyl- N (cid:1) -methylurea (Compound A)

Walter A. Korfmacher, Y. Wan, S. Umland, 2011 .

Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration

A. Nomeir, M. Cayen, E. Radwanski, 1995, Antimicrobial agents and chemotherapy.

Pharmacokinetics of the active antifungal enantiomer, SCH 42427 (RR), and evaluation of its chiral inversion in animals following its oral administration and the oral administration of its racemate genaconazole (RR/SS).

A. Nomeir, E. Radwanski, Chin-chung Lin, 2002, Chirality.

Chiral high-performance liquid chromatographic analysis of antifungal SCH 56592 and evaluation of its chiral inversion in animals and humans.

A. Nomeir, L. Heimark, C. Lin, 2000, Chirality.

Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2.

A. Nomeir, C. Lin, G. Krishna, 2001, International journal of pharmaceutics.

Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery.

Walter A. Korfmacher, R. Morrison, A. Nomeir, 2009, Journal of pharmaceutical sciences.

Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors.

Lynn A. Hyde, W. Greenlee, Mark D. McBriar, 2013, Bioorganic & medicinal chemistry letters.

Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.

W. R. Bishop, T. Guzi, A. Nomeir, 1999, Bioorganic & medicinal chemistry.

Metabolism of chlordane in mammals.

A. Nomeir, N. P. Hajjar, 1987, Reviews of environmental contamination and toxicology.

The importance of radiochemical analysis of biological fluids before and after lyophilization from animals dosed with [3H]-labeled compounds in drug discovery

A. Nomeir, J. Palamanda, Li Wang, 2003 .

Comparative metabolism and disposition of furfural and furfuryl alcohol in rats.

A. Nomeir, M. Mccomish, D. Silveira, 1992, Drug metabolism and disposition: the biological fate of chemicals.

6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.

Z. Gu, H. Ren, A. Nomeir, 2015, Bioorganic & medicinal chemistry letters.

Disposition of the flame retardant 1,2-bis(2,4,6-tribromophenoxy)ethane in rats following administration in the diet.

A. Nomeir, B. Ghanayem, P. Markham, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Single and multiple dose pharmacokinetics of felbamate in the elderly.

A. Nomeir, P. Glue, A. Richens, 2003, British journal of clinical pharmacology.

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

Brian McKittrick, Yaolin Wang, Emma Lees, 2007, Bioorganic & medicinal chemistry letters.

Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.

J. Lachowicz, A. Nomeir, C. Morgan, 2006, Bioorganic & medicinal chemistry letters.

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.

M. Dwyer, A. Nomeir, R. Mazzola, 2016, Bioorganic & medicinal chemistry letters.

Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability.

Lynn A. Hyde, W. Greenlee, J. Clader, 2009, Bioorganic & medicinal chemistry letters.

Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease

W. Greenlee, J. Clader, A. Nomeir, 2007 .

Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors.

W. Greenlee, R. Xu, J. Clader, 2010, Bioorganic & medicinal chemistry letters.

Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease.

W. Greenlee, R. Xu, J. Clader, 2012, ACS medicinal chemistry letters.

The role of pharmacokinetics and metabolism in species sensitivity to neurotoxic agents.

A. Nomeir, M. Abou‐Donia, 1986, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma.

A. Nomeir, Josephine Lim, S. Indelicato, 2003, Journal of chromatography. A.

Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys

D. Loebenberg, A. Nomeir, M. Cayen, 2000, Antimicrobial Agents and Chemotherapy.

Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048).

Walter A. Korfmacher, D. Loebenberg, A. Nomeir, 2008, Journal of mass spectrometry : JMS.

High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum.

A. Nomeir, C. Lin, H. Kim, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Gas chromatographic determination of 2-chloro-1-[[4-[(2,6-dichlorophenoxy)methyl]phenyl]methoxy]-4-methoxybenzene (SCH 48973), a potent anti-picornaviral agent, in dog serum

A. Nomeir, C. Buggé, C. Lin, 1999 .

Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended‐Release Tablets in Healthy Volunteers

A. Nomeir, M. Cayen, E. Radwanski, 1996, Journal of clinical pharmacology.

Utility of mass spectrometry for in-vitro ADME assays.

A. Nomeir, Amin A Nomeir, Inhou Chu, 2006, Current drug metabolism.

Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats

Walter A. Korfmacher, W. H. Barr, K. Cox, 1999 .

Comparative metabolism and disposition of ethyl carbamate (urethane) in male Fischer 344 rats and male B6C3F1 mice.

H. Matthews, A. Nomeir, J. M. Sanders, 1989, Toxicology and applied pharmacology.

Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma.

A. Nomeir, P. kumari, Hong Kim, 2002, Journal of pharmaceutical and biomedical analysis.

Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors

Ruo Xu, Zhiqiang Zhao, Murali Rajagopalan, 2007 .

Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.

Ramesh Kakarla, Guangming Chen, Song Huang, 2014, Journal of medicinal chemistry.

Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections

A. Nomeir, M. Cayen, E. Radwanski, 1997, Antimicrobial agents and chemotherapy.

In vitro degradation of malathion by mouse liver.

A. Nomeir, W. Dauterman, 1978, Biochemical pharmacology.

Studies on the optical isomers of EPN and EPNO

A. Nomeir, W. Dauterman, 1979 .

Protein Binding-dependent Decreases in hERG Channel Blocker Potency Assessed by Whole-Cell Voltage Clamp in Serum

A. Nomeir, T. Priestley, S. Sorota, 2010, Journal of cardiovascular pharmacology.

Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery.

Walter A. Korfmacher, K. Ng, K. Cox, 2001, Rapid communications in mass spectrometry : RCM.

New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.

P. Kirschmeier, Ming Liu, A. Nomeir, 2014, Bioorganic & Medicinal Chemistry Letters.

The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

Chuang Lu, Heidi J Einolf, Y. Wong, 2009, Drug Metabolism and Disposition.

Effects of felbamate on the pharmacokinetics of a low‐dose combination oral contraceptive

A. Nomeir, P. Glue, E. Radwanski, 1995, Clinical pharmacology and therapeutics.

Toxicological effects of gossypol

A. Nomeir, M. Abou‐Donia, 1985 .

Gossypol: High-performance liquid chromatographic analysis and stability in various solvents

A. Nomeir, M. Abou‐Donia, 1982 .

Photodecomposition of gossypol by ultraviolet irradiation

A. Nomeir, M. Abou‐Donia, 1985 .

Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.

W. R. Bishop, A. Nomeir, F. G. Njoroge, 2006, Bioorganic & medicinal chemistry letters.

Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.

W. R. Bishop, R. Doll, A. Nomeir, 1998, Journal of medicinal chemistry.

Effect of Felbamate on the Pharmacokinetics of Lamotrigine

A. Nomeir, P. Glue, C. Banfield, 1996, Journal of clinical pharmacology.

Small conformationally restricted piperidine N-arylsulfonamides as orally active gamma-secretase inhibitors.

Zhiqiang Zhao, William J Greenlee, Murali Rajagopalan, 2007, Bioorganic & medicinal chemistry letters.

Metabolism and disposition of a single oral dose of S_,S, S-TRI-n-butyl phosphorotrithioate (DEF) in hens

A. Nomeir, M. Abou‐Donia, 1983 .

Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Walter A. Korfmacher, W. R. Bishop, J. Catino, 1998, Cancer research.

Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.

Walter A. Korfmacher, W. R. Bishop, J. Chen, 1998, Journal of medicinal chemistry.

Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.

W. R. Bishop, J. Catino, M. Malkowski, 1997, Journal of medicinal chemistry.

Bridgehead Modification of Trihalocycloheptabenzopyridine Lead to a Potent Farnesyl Protein Transferase Inhibitor with Improved Oral Metabolic Stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2005 .

Pharmacokinetic Drug Interaction Study: Administration of Ceftibuten Concurrently with the Antacid Mylanta Double‐Strength Liquid or With Ranitidine

A. Nomeir, E. Radwanski, D. Cutler, 1998, American journal of therapeutics.

Absorption, distribution, excretion and metabolism of a single oral dose of [14C]tri-o-cresyl phosphate (TOCP) in the male rat.

A. Nomeir, M. Abou‐Donia, H. Makkawy, 1990, Toxicology.

Absorption, distribution, and elimination of a single oral dose of [14C]tri-o-cresyl phosphate in hens.

A. Nomeir, M. Abou‐Donia, E. Suwita, 1990, Toxicology.

Studies on the metabolism of the neurotoxic tri-o-cresyl phosphate. Distribution, excretion, and metabolism in male cats after a single, dermal application.

A. Nomeir, M. Abou‐Donia, M B Abou-Donia, 1986, Toxicology.

Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Pulmonary absorption and disposition of [14C]thiophene in rats following nose-only inhalation exposure.

A. Nomeir, P. Markham, M. Chadwick, 1993, Journal of toxicology and environmental health.

Structure-activity studies on the mutagenicity of tris(2,3-dibromopropyl) phosphate (Tris-BP) and its metabolites in Salmonella.

E. Zeiger, D. Pagano, A. Nomeir, 1982, Environmental mutagenesis.

Pathological and biochemical effects of dimethyl hydrogen phosphite in Fischer 344 rats.

A. Nomeir, L. Uraih, 1988, Fundamental and applied toxicology : official journal of the Society of Toxicology.

High-performance liquid chromatographic analysis of the D4 receptor antagonist SCH 66712 in rat plasma.

A. Nomeir, C. Lin, H. Kim, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry.

Walter A. Korfmacher, A. Nomeir, M. Bryant, 1997, Journal of chromatography. A.

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.

James I. Fells, E. Asante-Appiah, C. Coburn, 2016, Bioorganic & medicinal chemistry letters.

Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.

A. Nomeir, C. Lin, J. Palamanda, 2000, Drug metabolism and disposition: the biological fate of chemicals.

In vitro metabolism of EPN and EPNO in susceptible and resistant strains of house flies

A. Nomeir, E. Hodgson, W. Dauterman, 1980 .

In vitro metabolism of EPN and EPNO by mouse liver

A. Nomeir, W. Dauterman, 1979 .

Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer liquid chromatography/tandem mass spectrometry system.

R. Morrison, A. Nomeir, Tongtong Liu, 2003, Rapid communications in mass spectrometry : RCM.

Disposition, pharmacokinetics, and metabolism of a dermal dose of [14C]2,5-hexanedione in hens.

A. Nomeir, M. Abou‐Donia, E. Suwita, 1987, Drug Metabolism And Disposition.

Analysis of n-hexane, 2-hexanone, 2,5-hexanedione, and related chemicals by capillary gas chromatography and high-performance liquid chromatography.

A. Nomeir, M. Abou‐Donia, 1985, Analytical biochemistry.

Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction

E. J. Arthur, B. F. Butler, Catherine S. Mocny, 2011, Drug Metabolism and Disposition.

Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction

E. J. Arthur, B. F. Butler, Catherine S. Mocny, 2011 .

Studies on the metabolism of the neurotoxic tri-o-cresyl phosphate. Synthesis and identification by infrared, proton nuclear magnetic resonance and mass spectrometry of five of its metabolites.

A. Nomeir, M. Abou‐Donia, 1986, Toxicology.

Identification of CYP Mechanism-Based Inhibitors

A. Nomeir, L. Favreau, J. Palamanda, 2004 .

Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.

A. Nomeir, C. Casciano, R. Clement, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics of pseudoephedrine in rats, dogs, monkeys and its pharmacokinetic-pharmacodynamic relationship in a feline model of nasal congestion.

Walter A. Korfmacher, M. Corboz, R. Morrison, 2010, Drug Metabolism Letters.

Disposition of [14C]tri-o-cresyl phosphate and its metabolites in various tissues of the male cat following a single dermal application.

A. Nomeir, M. Abou‐Donia, 1984, Drug metabolism and disposition: the biological fate of chemicals.

High-performance liquid chromatographic analysis on radial compression column of the neurotoxic tri-o-cresyl phosphate and metabolites.

A. Nomeir, M. Abou‐Donia, 1983, Analytical biochemistry.

Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo.

Lynn A. Hyde, W. Greenlee, Xiaohong Zhu, 2012, Journal of medicinal chemistry.

Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Bioorganic & Medicinal Chemistry.

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

W. R. Bishop, D. Hicklin, G. Scapin, 2016, ACS medicinal chemistry letters.

In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor

E. Lees, P. Kirschmeier, Yaolin Wang, 2007 .

Chapter 5 In vitro dmpk screening in drug discovery, role of lc-ms/ms

A. Nomeir, Inhou Chu, 2005 .

In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Lynn A. Hyde, G. Higgins, J. Clader, 2013, International journal of Alzheimer's disease.

Biochemical Oxidation of Methyl Group of Toluene Derivatives in the Housefly and the Egyptian Cotton Leafworm

A. Nomeir, M. Eldefrawi, N. Bakry, 2009 .

Pharmacokinetic interaction studies between felbamate and vigabatrin.

A. Nomeir, P. Glue, E. Radwanski, 1995, British journal of clinical pharmacology.

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.

E. Asante-Appiah, C. Coburn, M. Dwyer, 2016, Bioorganic & medicinal chemistry letters.

Development and validation of an LC-MS-MS method for the simultaneous determination of sulforaphane and its metabolites in rat plasma and its application in pharmacokinetic studies.

A. Kong, A. Nomeir, T. Khor, 2011, Journal of Chromatographic Science.

Liquid chromatographic analysis in mouse, dog and human plasma; stability, absorption, metabolism and pharmacokinetics of the anti-HIV agent 2-chloro-5-(2-methyl-5,6-dihydro-1,4-oxathiin-3-yl carboxamido) isopropylbenzoate (NSC 615985, UC84).

A. Nomeir, J. Covey, N. F. Ferrala, 1998, Journal of pharmaceutical and biomedical analysis.

The metabolism and disposition of tris(1,3-dichloro-2-propyl) phosphate (Fyrol FR-2) in the rat.

H. Matthews, A. Nomeir, S. Kato, 1981, Toxicology and applied pharmacology.

Effect of dose on the percutaneous absorption of 2- and 4-chloronitrobenzene in rats.

A. Nomeir, D. Silveira, P. Markham, 1992, Drug metabolism and disposition: the biological fate of chemicals.